Viking Therapeutics (VKTX) Convertible Debt (2014 - 2018)
Viking Therapeutics (VKTX) posted Convertible Debt of $1.5 million for Q1 2018, little changed sequentially from $1.5 million in Q4 2017, and down 59.6% YoY from $3.7 million in Q1 2017.
Viking Therapeutics (VKTX) Convertible Debt (2014 - 2018) Analysis & Trends
Viking Therapeutics has reported Convertible Debt for 5 years, with the latest figure at $1.5 million in Q1 2018.
- Quarterly Convertible Debt fell 59.6% year-over-year to $1.5 million in Q1 2018, while the trailing twelve-month figure through Mar 2018 was $1.5 million (down 59.6% YoY) and the FY2017 annual result came in at $1.5 million, changed 0.0% from the prior year.
- Convertible Debt steadied at $1.5 million in Q1 2018 per VKTX's latest filing, from $1.5 million in the prior quarter.
- Over five years, Convertible Debt peaked at $3.7 million in Q1 2017 and troughed at $1.3 million in Q4 2014.
- A 5-year average of $1.8 million and a median of $1.5 million in 2016 frame the typical range for Convertible Debt.
- The sharpest annual moves came in 2016 and 2018: Convertible Debt surged 119.57% in 2016, then tumbled 59.6% in 2018.
- Over 5 years, Convertible Debt stood at $1.3 million in 2014, then jumped by 70.2% to $2.2 million in 2015, then slumped by 30.28% to $1.5 million in 2016, then changed by 0.0% to $1.5 million in 2017, then changed by 0.0% to $1.5 million in 2018.
- According to Business Quant data, Convertible Debt over the past three periods registered $1.5 million, $1.5 million, and $1.5 million for Q1 2018, Q4 2017, and Q3 2017 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 1.50 Mn |
| Dec 31, 2017 | 1.50 Mn |
| Sep 30, 2017 | 1.50 Mn |
| Jun 30, 2017 | 1.50 Mn |
| Mar 31, 2017 | 3.71 Mn |
| Dec 31, 2016 | 1.50 Mn |
| Sep 30, 2016 | 1.50 Mn |
| Jun 30, 2016 | 1.50 Mn |
| Mar 31, 2016 | 3.14 Mn |
| Dec 31, 2015 | 2.15 Mn |
| Mar 31, 2015 | 1.43 Mn |
| Dec 31, 2014 | 1.26 Mn |